Hearthwell

Public record · Texas

Texas Research Timeline

A careful chronological record of Texas’s public ibogaine initiative, from policy discussion and appropriations to institutional agreements, announced trials, and federal response.

Hands held together during a quiet discussion related to ibogaine research in Texas
Context matters: public research activity is not the same as legal, routine treatment access.
Public record
first Dates · status · source context

Scope of record

Read the timeline by status, not promise.

This page distinguishes completed public actions from announcements, planned studies, and introduced legislation. It does not infer future approval, clinical outcomes, or the availability of treatment. For broader context about the subject and its legal setting, Hearthwell’s Texas ibogaine overview separates research questions from public-access claims.

Ibogaine is listed as a Schedule I controlled substance in the United States; the DEA’s drug scheduling explanation describes the federal framework that still governs possession and use outside authorized research. The historical and pharmacological background is also summarized in Wikipedia’s ibogaine entry, though public summaries are not substitutes for regulatory records.

Texas interest has unfolded alongside questions people may have about international and non-U.S. settings. Comparisons with ibogaine treatment costs in Mexico should not be treated as evidence that any option is regulated, medically appropriate, or lawful for a particular person.

Three reading rules

What this record does—and does not—establish.

The relevant public documents identify commitments, institutional steps, and proposed research. They do not by themselves establish safety, effectiveness, availability, or federal approval.

I

Appropriations are commitments

A state appropriation can authorize and fund work. It is not a clinical finding, an approved protocol, or a guarantee that a planned study will enroll participants on a particular date.

II

Agreements are institutional steps

University and consortium announcements indicate collaboration and planning. Their practical significance depends on later protocol, regulatory, and trial-registration details.

III

Access remains separate

Research activity should be kept distinct from commercial availability. That distinction is central to the research versus access guide, especially when evaluating claims about options outside a study.

Chronological record

Policy discussion to the 2026 horizon.

Entries below use cautious status labels. “Announced” and “planned” describe public statements of intent; they are not presented as completed research, reported outcomes, or regulatory determinations.

  1. Public discussion

    Veterans, policy advocates, and lawmakers elevate ibogaine research as a Texas issue.

    Public conversations increasingly connected ibogaine research with the needs of veterans and others affected by substance-use and mental-health conditions. The policy focus was research infrastructure rather than a declaration that ibogaine treatment was legally available in Texas. Questions about terminology can also complicate searches; other names used for ibogaine may appear in public-facing material without changing the underlying legal classification.

  2. Completed public action

    Texas appropriates public funding for ibogaine clinical research.

    The Texas Legislature’s enacted budget process placed ibogaine research on the state policy agenda through a major appropriation intended to support clinical research. The public significance is the state commitment to a research effort; it does not itself authorize general treatment. Budget measures and enacted laws are available through the Texas Legislature’s official public portal.

  3. Announced

    The Texas Ibogaine Initiative and a research consortium are publicly described.

    Public announcements described a consortium model intended to organize Texas-based ibogaine research and translate a state-supported initiative into institutional work. A consortium announcement is a meaningful coordination milestone, but it should not be read as a completed clinical trial or a reported efficacy result.

  4. Announced

    UTHealth Houston is identified in public institutional planning.

    UTHealth Houston’s participation was publicly associated with the initiative’s research direction. Institutional participation signals planning capacity, while specific trial conduct still depends on protocol development and the applicable federal review pathway. For people comparing claims elsewhere, references to an ibogaine treatment facility in Mexico belong to a separate access and jurisdictional context.

  5. Announced

    UTMB Health is publicly associated with the research collaboration.

    Public reporting and institutional communications described UTMB Health agreements or collaboration within the Texas effort. Such an agreement documents an organizational step; it is not proof that a particular participant-facing program has begun or that an investigational product has received approval.

  6. Planned / announced

    Clinical-trial development is described in phases rather than as a completed result.

    Public discussion has described an intended clinical development pathway, including early-stage work and later research phases. Under the FDA framework, clinical investigation of an investigational drug commonly proceeds through structured development and review; the FDA’s Investigational New Drug application guidance explains why planned studies and eventual approval are distinct events.

  7. Introduced federal legislation

    The IBOGAINE Act, H.R. 9559, enters the federal legislative record.

    The introduction of H.R. 9559, known as the IBOGAINE Act, is a federal legislative milestone. An introduced bill is not enacted law and does not alter drug scheduling or create routine treatment access. Its formal status and text can be checked through the official Congress.gov record system.

  8. Record to be updated

    Future entries require public documentation.

    Later milestones may include trial registrations, institutional notices, regulatory submissions, published results, or changes in law. Until those records exist, they should remain described as proposed or unverified. Marketing language around ibogaine treatment centers in the United States does not establish that a Texas research initiative has created a licensed or FDA-approved treatment pathway.

Institutional record

A research structure, not a treatment promise.

Texas’s publicly described approach places universities and coordinated research activity at the center of the initiative. That structure matters because formal human research has defined oversight and documentation pathways; it does not collapse the difference between an announced study and a general public service.

“Announced,” “planned,” and “introduced” are factual status words—not predictions.

That same caution helps when reviewing international claims, including descriptions of ibogaine-related access in Canada. Different jurisdictions, providers, and websites may use similar language while operating under different rules and levels of oversight.

Verification framework

A practical way to check the next milestone.

When a new claim appears, locate its source before treating it as evidence of access or effectiveness. The research context is only one part of the larger decision landscape; Hearthwell’s plain-language guidance framework explains how the site distinguishes legal context, safety questions, and public claims without functioning as a treatment provider.

For company and market narratives, a page about ibogaine-related stock information may describe investor interest, but it does not independently verify clinical outcomes, state policy, or participant availability.

Questions of scope

What the timeline cannot answer.

These answers keep the record bounded by what public documents can support. They are not medical or legal advice.

Does a state research initiative mean ibogaine is approved for treatment in Texas?

No. State-supported research activity and federal drug approval are different matters. Ibogaine remains a Schedule I controlled substance under federal law, and an announcement of research does not establish routine legal access or an approved treatment.

What does announced or planned mean on this timeline?

It marks a proposal, appropriation, agreement, bill introduction, or public statement rather than a completed trial, reported outcome, regulatory approval, or operating treatment program.

Where can someone look for a formal study record?

ClinicalTrials.gov is the U.S. government registry for many clinical studies and can help distinguish a registered study from a general public announcement. A registry listing still needs to be read for status, eligibility, location, and sponsor information.

Recordkeeping principle

Follow the document trail.

The Texas initiative deserves precise attention: public funding and institutional coordination are consequential, while claims about approval, outcomes, or access require their own evidence.

Hearthwell Independent guidance on ibogaine research, policy, risks, and access.